Coya Therapeutics, Inc. COYA
3.23 USD +0.02 (+0.47%)
Nov 12, 2026, 2:49 PM EST
3.05 Day range 3.41
2.72 52-week range 6.62
- YTD
- -44.40%
- 1 year
- -47.04%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.- benzinga.com Coya Therapeutics Q3 EPS $(0.45) Misses $(0.34) Estimate, Sales $234.134K Beat $85.714K Estimate Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.34) by 32.35 percent. This is a 246.15 percent decrease over losses…
businesswire.com Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in…- benzinga.com Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individualsThe Company believes…
benzinga.com Coya Therapeutics Plans To Initiate Open-Label Extension Of Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Treatment Of Amyotrophic Lateral Sclerosis OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash…- benzinga.com Coya Therapeutics Announces Full Enrollment Of Planned 120 Participants In Phase 2/3 ALSTARS Trial Evaluating COYA 302 For Potential Treatment Of Amyotrophic Lateral Sclerosis 120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible participants already in active screening will be allowed to enrollTopline data from 24-week…
benzinga.com BTIG Reiterates Buy on Coya Therapeutics, Maintains $16 Price Target BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.
benzinga.com Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302 Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional participants continue to roll over into the active extension arm of the trialCOYA 302 has received…- benzinga.com Coya Therapeutics Announces Publication Of Preclinical Results For COYA 303 In International Journal Of Molecular Sciences; Results Show Complementary Immunomodulatory Effects In Peripheral And CNS Inflammation Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or…
benzinga.com Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target.
benzinga.com Coya Therapeutics Q2 EPS $(0.28) Beats $(0.34) Estimate, Sales $243.745K Beat $100.000K Estimate Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of…- benzinga.com Coya Therapeutics To Present Overview Of Ongoing ALSTARS Trial At European Network To Cure ALS June 24-26 Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T Cells And Neuroinflammation In ALSAuthors: Tyrell J. Simkins, DO, PhD; Fred Grossman, DO; Stanley…
benzinga.com Coya Therapeutics Initiates Blinded Extension Phase Of Its ALSTARS Trial; Patients Who Complete The 24-Week Placebo-Controlled, Double-Blind Phase Enter The Blinded Extension Phase Of The Study Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded…
benzinga.com This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONTO rated Buy with $350 PT by Deutsche Bank.
benzinga.com Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.- benzinga.com Coya Therapeutics Launches $30M At-The-Market Stock Offering Agreement With Leerink Partners On May 12, 2026, Coya Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC, as sales agent ("Leerink Partners"), pursuant to which the…
- benzinga.com Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.41) by 21.95 percent. This is a 27.27 percent increase over losses of…
- benzinga.com Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with…
- benzinga.com Coya Therapeutics Announces Publication Demonstrating That COYA 302 Increased Three Biomarkers In ALS Patients Compared To Controls The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $18 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Coya Therapeutics Commences ~$11.1M Offering Of 2.522M Common Shares At $4.40/Share; Dr. Reddy's Laboratories And Greenlight Capital Are Investors In Offering Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,…
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 201 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday During the Friday's sesion, 157 stocks hit new 52-week lows.- benzinga.com Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday, 24 stocks hit new 52-week lows.